Japan has approved the Leqembi Pen for once-weekly at-home administration in early Alzheimer’s disease, potentially reducing infusion-center dependence while giving Biogen and Eisai another way to differentiate lecanemab from rival anti-amyloid therapies.
Biomarkers can speed drug approvals, but weak validation can haunt sponsors. FDA and EMA are tightening the path from signal to endpoint.
Belzutifan plus lenvatinib outperforms cabozantinib in Phase 3 renal cell carcinoma data. Find out what this changes for post-immunotherapy care.
Leqembi Iqlik gets FDA Priority Review for at-home Alzheimer’s treatment initiation. Find out what this could mean for patients, payers, and the care model.